CAI vs GRAL: stock comparison and AI forecast
Caris Life Sciences, Inc. (CAI) and Grail, Inc. (GRAL) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
CAI Caris Life Sciences, Inc.
- Price
- $34.33 +80.7% · 6M
- Market Cap
- $9.70B
- P/E Ratio
- 7.2x
- Size
- mid-cap
- AI Forecast
- NO CURRENT FORECAST
GRAL Grail, Inc.
- Price
- $133.76 +140.3% · 6M
- Market Cap
- $6.23B
- P/E Ratio
- –
- Size
- mid-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Six-month price performance
Closing prices rebased to 100 at the start of the window.
Key facts
- CAI is 1.6 times larger than GRAL by market capitalization ($9.70B against $6.23B).
- Over the last six months GRAL returned +140.3% and CAI +80.7%.
- CAI carries 1.08 times debt per unit of equity, against 0.12 times for GRAL.
- Both companies share the SEC industry classification Services-Medical Laboratories.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | CAI | GRAL |
|---|---|---|
| Market Cap | $9.70B | $6.23B |
| P/E Ratio | 7.23x | – |
| P/B Ratio | 16.40x | 2.45x |
| EPS | $4.75 | $-9.68 |
| Book Value/Share | $2.09 | $56.93 |
| Revenue/Share | $3.93 | $3.70 |
| FCF/Share | $0.44 | $-6.63 |
Profitability & Margins
| Metric | CAI | GRAL |
|---|---|---|
| ROE | – | -15.4% |
| ROA | – | -13.8% |
| ROIC | 9.2% | -20.3% |
| Operating Margin | 8.6% | -338.4% |
| Net Margin | – | -236.9% |
| EBT Margin | 0.2% | -320.4% |
| Tax Rate | -4.5% | 26.0% |
Financial Health
| Metric | CAI | GRAL |
|---|---|---|
| Current Ratio | 5.53x | 10.95x |
| D/E Ratio | 1.08x | 0.12x |
| Financial Leverage | 2.08x | 1.12x |
| Interest Coverage | 2.9x | – |
| Working Capital | $866M | $831M |
Cash Flow
| Metric | CAI | GRAL |
|---|---|---|
| Operating Cash Flow | $169M | -$295M |
| Free Cash Flow | $124M | -$296M |
| Capital Spending | -$45M | -$1M |
| FCF/Sales | 11.2% | -179.2% |
| CapEx/Sales | 4.0% | 0.9% |
Operational Efficiency
| Metric | CAI | GRAL |
|---|---|---|
| Asset Turnover | 0.90x | 0.06x |
| Receivables Turnover | 9.5x | 8.4x |
| Fixed Assets Turnover | 11.6x | 3.7x |
| Days Sales Outstanding | 38 days | 44 days |
Income Statement
| Metric | CAI | GRAL |
|---|---|---|
| Total Revenue | $1.11B | $165M |
| Operating Income | $95M | -$559M |
| Net Income | – | -$392M |
| R&D Expense | $140M | $191M |
| SG&A Expense | $672M | $330M |
Dividend & Shareholder Information
| Metric | CAI | GRAL |
|---|---|---|
| Shares Outstanding | 283M | 45M |
CAI vs GRAL: stock comparison and AI forecast
Which is bigger, CAI or GRAL?
CAI is 1.6 times larger than GRAL by market capitalization ($9.70B against $6.23B).
Which stock performed better over the last six months, CAI or GRAL?
Over the last six months GRAL returned +140.3% and CAI +80.7%.
Which one does Intratio's AI model rank higher, CAI or GRAL?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.